ProQR Therapeutics N.V. (PRQR) PT Lowered to $18 at Chardan Capital Markets

Chardan Capital Markets analyst Keay Nakae lowered the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $18.00 (from $20.00) while maintaining a Buy rating.

The analyst commented, ": We continue to believe that future progress updates from the pipeline programs, beyond the readout of data from ILLUMINATE, could serve as value creation events for the stock over the next 12-18 months. Our price target reduction primarily reflects the increased share count dilution following the recent equity offering."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities